Skip to content

Author

V. Kandi

We have 2 of 247 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives

Modern CML management has transitioned from uniform kinase inhibition toward highly individualized survivorship, and Optimizing long-term quality of life relies on aligning tyrosine kinase inhibitor selection with patient-specific comorbidities, implementing response-adjusted dosing, and utilizing well-defined clinical...

V. Pinnelli, Surendra Babu Thangachi, Jayashankar Chinnappa Anjanappa et al. · 0 citations
Review Open access Aug 2026

Advances in therapeutics and vaccines for Marburg virus disease: challenges and future directions.

The human monoclonal antibody MR191N provides complete post-exposure protection in non-human primates and necessitates adaptive trial designs, expanded diagnostic models, and synergistic combination therapies to address MVD.

V. Kandi, F. Branda, Mohammed Alissa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.